Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Compare

1,038 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AVTX Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Avalo

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AVTX Stock 12 Month Forecast

Average Price Target

$38.00

▲(122.09% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $38.00 with a high forecast of $48.00 and a low forecast of $25.00. The average price target represents a 122.09% change from the last price of $17.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","49":"$49","14.5":"$14.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.5,26,37.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.16,20.455384615384617,22.75076923076923,25.046153846153846,27.341538461538462,29.63692307692308,31.932307692307695,34.22769230769231,36.52307692307693,38.81846153846154,41.113846153846154,43.409230769230774,45.70461538461539,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.16,19.686153846153847,21.212307692307693,22.73846153846154,24.264615384615386,25.790769230769232,27.316923076923075,28.84307692307692,30.369230769230768,31.895384615384614,33.42153846153846,34.94769230769231,36.473846153846154,{"y":38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.16,18.686153846153847,19.212307692307693,19.73846153846154,20.264615384615386,20.790769230769232,21.31692307692308,21.84307692307692,22.369230769230768,22.895384615384614,23.42153846153846,23.947692307692307,24.473846153846154,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.43,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$48.00

Average Price Target$38.00

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Julian Harrison

BTIG

$40

Buy

133.78%

Upside

Reiterated

01/02/26

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (NYSE: SOLV), Avalo Therapeutics (NASDAQ: AVTX) and Lifestance Health Group (NASDAQ: LFST)

Joseph Catanzaro

Mizuho Securities

$39

Buy

127.94%

Upside

Initiated

12/18/25

Avalo Therapeutics initiated with an Outperform at MizuhoAvalo Therapeutics initiated with an Outperform at Mizuho

Mitchell Kapoor

H.C. Wainwright

$25

Buy

46.11%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Anavex Life Sciences (NASDAQ: AVXL)

Yasmeen Rahimi

Piper Sandler

$48

Buy

180.54%

Upside

Reiterated

10/17/25

Piper Sandler Sticks to Its Buy Rating for Avalo Therapeutics (AVTX)

Stacy Ku

TD Cowen

Buy

―

Reiterated

10/14/25

Leland Gershell

Oppenheimer

$35

Buy

104.56%

Upside

Reiterated

09/29/25

Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Initiated

08/15/25

Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$53.59→$19.81

Buy

15.75%

Upside

Initiated

08/06/25

Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank

Alex Thompson CFA

Stifel Nicolaus

$36

Buy

110.40%

Upside

Reiterated

07/28/25

Stifel Nicolaus Keeps Their Buy Rating on Avalo Therapeutics (AVTX)

Robert Driscoll

Wedbush

$18

Buy

5.20%

Upside

Initiated

02/20/25

Avalo Therapeutics initiated with an Outperform at WedbushAvalo Therapeutics initiated with an Outperform at Wedbush

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Julian Harrison

BTIG

$40

Buy

133.78%

Upside

Reiterated

01/02/26

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (NYSE: SOLV), Avalo Therapeutics (NASDAQ: AVTX) and Lifestance Health Group (NASDAQ: LFST)

Joseph Catanzaro

Mizuho Securities

$39

Buy

127.94%

Upside

Initiated

12/18/25

Avalo Therapeutics initiated with an Outperform at MizuhoAvalo Therapeutics initiated with an Outperform at Mizuho

Mitchell Kapoor

H.C. Wainwright

$25

Buy

46.11%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX) and Anavex Life Sciences (NASDAQ: AVXL)

Yasmeen Rahimi

Piper Sandler

$48

Buy

180.54%

Upside

Reiterated

10/17/25

Piper Sandler Sticks to Its Buy Rating for Avalo Therapeutics (AVTX)

Stacy Ku

TD Cowen

Buy

―

Reiterated

10/14/25

Leland Gershell

Oppenheimer

$35

Buy

104.56%

Upside

Reiterated

09/29/25

Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)

Prakhar Agrawal

Cantor Fitzgerald

Buy

―

Initiated

08/15/25

Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$53.59→$19.81

Buy

15.75%

Upside

Initiated

08/06/25

Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank

Alex Thompson CFA

Stifel Nicolaus

$36

Buy

110.40%

Upside

Reiterated

07/28/25

Stifel Nicolaus Keeps Their Buy Rating on Avalo Therapeutics (AVTX)

Robert Driscoll

Wedbush

$18

Buy

5.20%

Upside

Initiated

02/20/25

Avalo Therapeutics initiated with an Outperform at WedbushAvalo Therapeutics initiated with an Outperform at Wedbush

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avalo Therapeutics

1 Month

xxx

Success Rate

4/5 ratings generated profit

Average Return

+9.88%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.88% per trade.

3 Months

xxx

Success Rate

3/5 ratings generated profit

Average Return

+34.92%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +34.92% per trade.

1 Year

Yasmeen RahimiPiper Sandler

Success Rate

5/5 ratings generated profit

Average Return

+92.20%

reiterated a buy rating 3 months ago

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +92.20% per trade.

2 Years

xxx

Success Rate

5/5 ratings generated profit

Average Return

+92.20%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +92.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVTX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AVTX has received 2 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. AVTX average Analyst price target in the past 3 months is 38.00.

Each month's total comprises the sum of three months' worth of ratings.

AVTX Financial Forecast

AVTX Earnings Forecast

Next quarter’s earnings estimate for AVTX is -$1.46 with a range of -$2.17 to -$0.94. The previous quarter’s EPS was -$2.19. AVTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AVTX has Performed in-line its overall industry.

AVTX Sales Forecast

Next quarter’s sales forecast for AVTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AVTX has Performed in-line its overall industry.

AVTX Stock Forecast FAQ

What is AVTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Avalo Therapeutics’s 12-month average price target is 38.00.

What is AVTX’s upside potential, based on the analysts’ average price target?

Avalo Therapeutics has 122.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AVTX a Buy, Sell or Hold?

Avalo Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Avalo Therapeutics’s price target?

The average price target for Avalo Therapeutics is 38.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $25.00. The average price target represents 122.09% Increase from the current price of $17.11.

What do analysts say about Avalo Therapeutics?

Avalo Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of AVTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

AVTX Analyst Ratings

AVTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avalo Therapeutics

AVTX Analyst Recommendation Trends

AVTX Financial Forecast

AVTX Earnings Forecast

AVTX Sales Forecast

AVTX Stock Forecast FAQ

Detailed List of Analyst Forecasts